Abstract: BACKGROUND: The combination of the severity of pediatric-onset inflammatory bowel disease (IBD) phenotypes and the need for intense medical treatment may increase the risk of malignancy and mortality, but evidence regarding the extent of the problem is scarce. Therefore, the Porto Pediatric IBD working group of ESPGHAN conducted a multinational-based survey of cancer and mortality in pediatric IBD. METHODS: A survey among pediatric gastroenterologists of 20 European countries and Israel on cancer and/or mortality in the pediatric patient population with IBD was undertaken. One representative from each country repeatedly contacted all pediatric gastroenterologists from each country for reporting retrospectively cancer and/or mortality of pediatric patients with IBD after IBD onset, during 2006-2011. RESULTS: We identified 18 cases of cancers and/or 31 deaths in 44 children (26 males) who were diagnosed with IBD (ulcerative colitis, n = 21) at a median age of 10.0 years (inter quartile range, 3.0-14.0). Causes of mortality were infectious (n = 14), cancer (n = 5), uncontrolled disease activity of IBD (n = 4), procedure-related (n = 3), other non-IBD related diseases (n = 3), and unknown (n = 2). The most common malignancies were hematopoietic tumors (n = 11), of which 3 were hepatosplenic T-cell lymphoma and 3 Ebstein-Barr virus-associated lymphomas. CONCLUSIONS: Cancer and mortality in pediatric IBD are rare, but cumulative rates are not insignificant. Mortality is primarily related to infections, particularly in patients with 2 or more immunosuppressive agents, followed by cancer and uncontrolled disease. At least 6 lymphomas were likely treatment-associated by virtue of their phenotype.
T he incidence of pediatric inflammatory bowel disease (PIBD) in European countries has risen significantly in the past 2 decades, as shown by several recent studies. [1] [2] [3] Over this same period, medical treatment of PIBD has changed considerably with a tendency for using more aggressive immunosuppressive medications earlier in the disease course. In addition, pediatric-onset IBD is more often extensive, more severe, and patients have a longer anticipated duration of disease, as compared with adults. 4, 5 Death and cancer from IBD in children are devastating but fortunately rare and may be because of factors related to the inflammation or those related to medical or surgical interventions. Disease-associated cancers are usually adenocarcinomas arising from chronic inflammation, whereas lymphoproliferative disorders (e.g., Ebstein-Barr virus [EBV]-associated lymphomas or hepatosplenic T-cell lymphomas [HSTCL] ) have been associated with specific treatments, most notably thiopurines. 6, 7 In addition, cervical cancer and skin cancers have been recognized as adverse events of immunosuppressive medications, including biologics.
The need to control active disease, decrease steroid exposure, and prevent complications has led to an increased exposure to thiopurines, biologics, and calcineurin inhibitors [8] [9] [10] and hesitation to combine biologics and immunomodulators for patients who failed monotherapy. 11 It is difficult to assess the risk of malignancy and mortality in small pediatric clinical trials with short-term follow-up. Therefore, the Porto Pediatric IBD working group of ESPGHAN conducted a multinational-based survey of malignancy and mortality in PIBD to assess the causes of mortality, the types of cancers that occur, and their association to disease-related factors or to medical or surgical interventions.
METHODS
This is a retrospective multinational multicenter study. The choice of a retrospective design was made based on the expected low incidence rate of the outcomes. A 6-year period was chosen, because it is reasonable to assume that recall bias of pediatricians Germany  145 ped GIs  70  8  6  3  England  75 ped GIs  NA  4  4  1  Wales  4 ped GIs  100  1  0  1  Scotland  10 ped GIs  100  2  1  2  Spain  115 ped GIs  90  4  3  1  Sweden  21 regions  62  4  3  1  The Netherlands  35 ped GIs  100  3  1  2  Poland  16 centers  100  3  3  1  Greece  15 centers  100  2  2  1  Czech Republic  27 ped GIs  100  2  2  0  Israel  61 ped GIs  69  2  2  0  Finland  15 ped GIs  100  2  1  1  Romania  15 ped GIs  100  2  2  0  Italy  35 ped GIs  94  2  1  1  Croatia  10 centers  100  1  0  1  Hungary  10 centers  100  1  0  1  France  27 centers  44  1  0  1  Belgium  11 centers  100  0  0  0  Switzerland  5 centers  60  0  0  0  Portugal  9 centers  100  0  0  0  Denmark  16 centers  56  0  0  0  Austria  14 ped GIs  50  0  0  0 Ped GI, pediatric gastroenterologist; NA, not available. is minimal when probing outcomes such as mortality and cancer within such period. Dedicated national representatives (1 per country) of 20 European countries and Israel were appointed. The representative contacted all pediatric gastroenterologists within each country through e-mail requesting for possible cases at least twice (unless all pediatric gastroenterologists had already responded on the first e-mail). Besides the e-mails, pediatric gastroenterology colleagues were personally approached during national meetings.
Inclusion criteria for reported cases were patients with IBD diagnosed before 19 years of age, who were diagnosed with any type of malignancy or mortality after disease onset of IBD but before the age of 19 years. To further minimize recall bias, we limited the reported cases to the 6 years preceding the survey (2006) (2007) (2008) (2009) (2010) (2011) .
For each reported case, a form was filled in and collected. A structured form of data ascertainment was completed for each reported case, including questions on patient characteristics, disease history, treatments, comorbidity, type of malignancy, and/or cause of death. In France (EPIMAD) and Germany together with Austria (CEDATA-GPGE), national IBD registries of malignancy and mortality have been identified and explored for further missed cases. Patients reported outside the time frame were excluded from analysis.
RESULTS
The 21 national representatives identified 44 children (18 with malignancy, 31 with mortality of which 5 died because of malignancy) from 15 countries ( Table 1 ). The percentage of the national pediatric gastroenterology colleagues who actively responded whether they had had any cases is recorded in Table 1 . Furthermore, the national representatives assumed, because of personal communication during meetings, that all pediatric gastroenterologists who did not respond to the e-mails did not have any patients fitting the inclusion criteria. The exploration of the national databases EPIMAD and CEDATA-GPGE did not reveal any additional cases. In the years 2006-2011; 7, 6, 4, 5, 3, and 16 cases have been reported, respectively. The precise year of mortality or development of cancer or mortality was unknown in 3 cases.
Malignancy
Patient characteristics and details of the 18 children developing a malignancy are shown in Tables 2 and 3 , respectively. The majority of patients (67%) had Crohn's disease (CD). Eleven out of 18 (61%) had developed a lymphoma or leukemia of which 3 were HSTCL and 3 EBV-positive lymphomas, which are typically associated with immunosuppression. These 6 patients had all been treated with thiopurines (ranging from 12 to 96 mo) until diagnosis, but one who had stopped thiopurines at least 3 months before HSTCL was diagnosed. Only 1 patient had also received 3 infliximab infusions, 5 years before the diagnosis of cancer. One patient with ulcerative colitis (UC) developed an adenocarcinoma of the colon at 16 years of age after a disease duration of 13 years. He had been diagnosed of UC at 3 years and of primary sclerosing cholangitis at 13 years of age. Another patient with UC developed cholangiocarcinoma at the age of 8 years, with a disease duration of 5 years, without known primary sclerosing cholangitis. Of those who died due to a malignancy, 4 out of 5 malignancies are likely associated with IBD or the treatment received (HSCTL [n ¼ 2], EBV-positive lymphoma [n ¼ 1], and 1 adenocarcinoma).
All 3 patients who developed HSTCL were males and had exposure to thiopurines ranging from 32 to 108 months; none received a biologic. Two of the 3 EBV-associated lymphomas received thiopurines before diagnosis, whereas the medical therapy for the third patient was not available.
Mortality
We identified 31 fatalities among patients during follow-up, and patient characteristics and details are shown in Tables 4 and 5 , respectively. The majority of patients (61%) had UC. The underlying cause for the infectious-related mortality cases (n ¼ 14) included sepsis (n ¼ 7, 47%) and opportunistic infections (n ¼ 4, 29%), such as candida and varicella virus. Cases of tuberculosis or Pnarmocystis jimveci pneumonia were not diagnosed.
Medications used in the 3 months preceding mortality of the 14 children who died because of infectious causes were given monotherapy with steroids (n ¼ 1, 7%) or thiopurine (n ¼ 1, 7%), combination therapy of 2 immunomodulators (n ¼ 11, 73%) (steroids and thiopurine [n Three out of the 14 patients (21%) were treated with total parenteral nutrition through a central venous access. All these patients had CD and had been treated with a biologic, in combination with either steroids, thiopurine, or MTX.
Three out of 5 patients who died due to cancer were probably treatment-related, these resulted from HSTCL (n ¼ 2) and EBV-positive lymphoma (n ¼ 1). One patient died due to a malignancy, which probably was disease-related, being colonic adenocarcinoma. The fifth patient had a primitive neuroectodermal tumor.
Four patients died because of uncontrolled disease activity as follows: 1 patient died because of complications of CD, which were not further specified; 1 patient developed toxic megacolon and sepsis; and 1 multiorgan failure (we could not ascertain if sepsis was present). The latter 2 patients were nonadherent to their medication. The fourth patient developed cardiomyopathy and a fatal thromboembolic event.
Three patients died because of procedure-related complications, including a perforation during surgical colectomy to treat toxic megacolon, pericardial tamponade during anesthesia, and a sepsis and cerebral thrombosis, shortly after total colectomy.
DISCUSSION
In the era of increased use of biologics and immunosuppressive medications, development of management strategies for IBD requires evidence for an effect of treatment and adverse outcomes, so that risk/benefit can be applied to the decision making process by clinicians. Biologics and immunosuppressants are used in combination quite frequently, whether combination therapy is superior to any individual therapy is still a matter of debate. 12 Recent large studies have shown that early immunosuppression decreases the risk for stricturing and penetrating disease and the need for surgery over 10 years of follow-up. 13 Although data regarding the risk for disease-associated complications such as stricturing, penetrating, or perianal disease are available, data regarding the risk for the most severe complications such as cancer and fatal disease are still lacking in children.
Malignancy
At least 6 lymphomas (HSTCL or EBV-positive lymphoma) were likely treatment-associated, by virtue of their phenotype. Pediatricians using immunosuppressants (typically thiopurines often in combination with anti-TNFs, although the patients developing HSTCL or EBV-positive lymphoma within this cohort were all treated with thiopurine monotherapy) should be aware of this rare but very serious complication.
Disease-related malignancies were likely in 2 patients who developed adenocarcinomas of the gastrointestinal tract. The third most common malignancy after HSTCL and EBV-positive lymphoma was Hodgkin lymphoma, which is common in adolescents regardless of IBD. The lack of a control group makes it impossible to elucidate how many of the Hodgkin cases are disease-specific. Interestingly enough, none of the malignancy-associated fatalities occurred during the use of a biologic. This may reflect the less frequent use and access in pediatric patients to biologics during the study period.
Although assuming significant underreporting bias (see limitations), IBD-associated malignancies seem rare. This probably reflects age-related risk, but also that disease-and therapy-associated malignancies require prolonged exposure to inflammation or drugs to occur. This was illustrated in a systematic review on the natural history of pediatric-onset IBD, 14 showing that cancers were reported in only 14 patients within 11 clinic/hospital-based studies. Twelve out of these 14 (86%) patients developed cancer after the age of 19 years. Six out of the 14 patients had CD, and they all developed colonic or small bowel adenocarcinoma except one who developed metastatic breast carcinoma, whereas 8 out of the 14 patients had UC, and they all developed colonic adenocarcinoma except one who developed cholangiocarcinoma.
The CESAME study on lymphoproliferative disorders in patients with IBD found an incidence of 9 per 10,000 patientyears among 5867 patients treated with thiopurines, most were the EBV-positive lymphoproliferative type. 15 The maximum risk was associated with older age and longer duration of disease.
A large Dutch study in 17,834 patients with IBD identified 44 lymphomas (only adult patients, diagnosed at mean age of 54 yr, only 1 patient with pediatric-onset CD at age of 17 yr), resulting in a relative risk of 1.27 (95% confidence interval, 0.92-1.68). 16 Nineteen of 44 patients (43%) were exposed to thiopurines. A total of 92% of patients (11/12) with EBV-positive lymphoma were treated with thiopurines compared with only 19% patients (4/21) with EBV-negative lymphoma, suggesting a strong relation between EBV-positive lymphoma and thiopurine use. This is in accordance with the EBV-positive lymphoma cases in our study cohort. Although there is evidence that IBD therapies in adult patients increase the risk of certain malignancies in patients with both CD and UC (lymphomas, HSTCL, and non melanoma skin cancer), the absolute incidence rate of these malignancies is low. 17 For example, the absolute incidence of non-Hodgkin's lymphoma is estimated to be 6.1 per 10,000 patient-years while on combination therapy of an immunosuppressor and anti-TNF in patients with CD in a meta-analysis. 18 Male patients under 35 years seem to be at particular risk of HSTCL, especially when exposed to either a thiopurine or thiopurine in combination with anti-TNF therapy. However, the estimated absolute risk for men ,35 years on combination therapy still is extremely low, being 1:3534. 19 The data from our study also seem to show that the risk is low, because only 3 patients with HSTCL were identified during a 6-year period in 20 countries, although thiopurine use was common during this time period.
In children, the risk for these malignancies seems even lower, but it is unknown whether it increases with age. A retrospective study on children and young adults with IBD found only 2 cases of lymphomas during childhood (males at age 12 and 18 yr, both treated with thiopurines) among 1374 patients with a mean followup of 4.8 years. 20 The incidence among thiopurine-exposed patients 
Mortality
We found that mortality is uncommon and is primarily related to the occurrence of infections. It is striking that the majority of patients were diagnosed with UC, although UC is considered to be curable by colectomy. Nine out of 19 (47%) patients with UC died because of an infectious complication. These fatalities may have been prevented by earlier surgical intervention when intensified medical treatment is ineffective (Fig. 1) . In addition, this could serve as an argument against sequential therapy in acute severe colitis (calcineurin inhibitors after infliximab or vice versa) instead of colectomy, as suggested in the recent ECCO/ESPGHAN guideline. 21 Most of the patients with fatal infections were treated with 2 or more immunomodulators (n ¼ 12, 86%), although this was only the case for 1 patient who developed cancer and for 6 (35%) patients who died because of causes other than infections. This illustrates the increased risk of infectious complications in patients on combination of immunomodulatory therapy. 22 Three of these 13 patients were at risk of infections by virtue of a central venous catheter. Whenever possible, enteral instead of parenteral nutrition should be used because a central venous catheter in immunesuppressed patients clearly is a risk.
To prevent opportunistic infections in children with IBD on immunosuppressive therapy, the recently published guidelines should be followed. 23, 24 These guidelines include assessment and correction of the patient's nutritional status because malnutrition is a concomitant risk factor for an opportunistic infection and optimization of immunizations before the initiation of immunosuppressive agents. For children with triple immunosuppressive therapy, cotrimoxazole prophylaxis against P. jiroveci is advised.
Limitations
This report is the first to assess major risks of PIBD in a large population, but it is not without limitations. The first limitation is the retrospective design of the study. It is almost certain that the reported cases are not a full list of fatalities and cancer in the included countries during the study period, but it is impossible to assess the rate of underreporting. Physicians treating pediatric patients with IBD may not have been contacted or may have not cooperated, but patients may have been treated by adult gastroenterologists at an age younger than 19 years as shown in the EUROKIDS registry, which makes it likely that many patients with IBD from the age of 15 years are diagnosed and treated by adult gastroenterologists. 25 We could not calculate if children with IBD were at increased risk for cancer or mortality because of the lack of a denominator (the number of children with IBD in each country and the risk for mortality in the underlying population).
Patients who died of other causes and did not show up for follow-up may have been missed because of lack of awareness. An additional limitation has to do with the age limitations within the study design. We assessed the burden of serious adverse outcome by the age of 19 years. However, it is plausible to assume that many developed a malignancy or died after that age, which still could be a consequence of the disease or treatment prescribed during childhood. In addition, we did not ascertain the denominator of treated PIBD during the same period. However, it was not the aim of the study to elucidate exact rates of adverse events but to bring to the attention of practicing gastroenterologists that serious adverse events of both the disease and treatment do occur and to highlight the ratio between these 2 competing groups. Although we do not know how many of the cancer cases are unrelated to the disease, at least 6 of the reported malignancies were clearly related to the disease or its treatment and probably some of the others also.
Taken together, the true case ascertainment of grave outcomes during childhood is probably higher than reported here. First, it is important to note that at least half of mortality cases reported were treatment-related, whereas approximately 1/6 were disease-related and 1/10 were procedure-related. Second, only 2 cases of mortality were because of surgical complications in UC, and more were related to uncontrolled disease or immunosuppressant treatment. However, more patients will have received medical than surgical treatment, which makes these numbers difficult to compare head-to-head. Still, it seems important to consider colectomy in every case of resistant disease requiring multiple immunosuppressant medications. 26 Many recent studies have focused on specific outcomes such as surgery, infection, or lymphomas; and depending on the outcome, advocate either earlier immunomodulation to prevent complicated disease and surgery or less immunomodulation to prevent medication-associated adverse events. Reports that just focus on cancer but not on severe disease outcome induce a bias. Because there is a lack of evidence-based guidance, physicians need to weigh all the different risks and propose a comprehensive strategy for young patients with a severe disease burden. 15, 21 We clearly need larger cohorts with prospective data collection to understand the risk of withholding treatment versus overtreatment, and this report should be regarded as a preliminary attempt to address the complex problem of the very rare but severe outcomes of PIBD.
